Open in interactive viewer → charts, metric popovers & call review

Pelthos Bought a Pipeline and the Market Took It Out on the Stock

Zelsuvmi's revenue went flat-to-down sequentially, management pivoted to a rare-disease gene therapy — and PTHS lost two-thirds of its value in three weeks.
PTHS · Earnings Call · 2026-11-12

A quarter that was fine, a stock that was not

Pelthos Therapeutics reported a decent third quarter on 2026-11-12: $15.2M of Zelsuvmi net product revenue, up 114% year-over-year, more than 40,000 units dispensed and 31,000-plus patients treated in five quarters since launch. On the surface, a micro-cap ($31.6M market cap) commercial-stage dermatology story hitting its stride. The tape says otherwise. PTHS has fallen 70.4% in 90 trading days and 78.5% from its November 2025 peak of $37.42, with the sharpest leg — roughly -57% — landing in the just three weeks around the October 30 Castle Creek Biosciences announcement. The quarter was not the story. The deal was.

The number nobody led with

Read the CFO's prepared remarks carefully and the growth narrative sags. “For the third quarter of 2026, we reported $15.2 million of net product revenue as compared to $15.4 million in the second quarter of 2026.” — John Gay, Chief Financial Officer · 2026-11-12 That is a sequential decline. Management's defense: “We would have had actually a positive revenue growth quarter-over-quarter if we hadn't done it. But we believe it's going to accelerate growth going forward” — Scott Plesha, Chief Executive Officer · 2026-11-12 — "it" being the new PBM contract that opened ~24M commercial covered lives with no prior authorization. The price of that access was visible: gross-to-net stepped from 29.6% to 31.5%, and management guided GTN into the mid-30s as further formulary coverage lands. So the growth was traded for access, deliberately, and the reported top-line paid for it. Worth flagging the pattern: the mid-30s GTN target has been management's refrain for at least three calls. “We feel very confident that the mid-30s is a good number going forward” — Scott Plesha, Chief Executive Officer · 2026-05-14 was the May framing; in August it was “we think we're going to go to the low to mid-30s here, later in the year here” — Scott Plesha, Chief Executive Officer · 2026-08-13. Q3 finally delivered the move — but as a cost, not a benefit. The mid 30 GTN became the mechanism by which a 114% yoy headline masks a flat-to-down sequential reality. Underlying demand is real but decelerating: prescriptions rose 4% sequentially (11,925 to 12,384), unique prescribers from 4,571 to 4,942, and management leaned hard on seasonality — the summer HCP-vacation effect. October was "our second highest month ever," up 4% from September. All plausible. None of it is the hypergrowth a 114% yoy print implies.

The pivot: from specialty pharma to biotech, in one signature

The real news is Castle Creek. On October 30 Pelthos signed to acquire a late-stage, redosable gene-modified cell therapy (D-Fi) for dystrophic epidermolysis bullosa — an orphan-designated, rare disease candidate with a Phase III ahead. The strategic logic is legible: management argues it can leverage its existing pediatric-dermatology commercial infrastructure, and the comparative benchmark is VYJUVEK, which management says did $127M in Q3 global net revenue and $1.1B since launch. The differentiation claim rests on not having a live virus orientation and a different dosing paradigm, plus a disease with an intense wound burden that drives multi-therapy use. Peter Greenleaf's framing of why now is the cleanest part of the call: “We could have gone out and done a deal, had it be a license or had it been a cash-based transaction where we would have had to raise money if we didn't have this commercial business.” — Peter Greenleaf, Executive Chairman · 2026-11-12 The pitch is that a cash-generating commercial base lets Pelthos absorb a late stage asset via stock-plus-milestones instead of a dilutive raise. Greenleaf was blunt that the market hasn't bought it: “there are very few comps out there that you can find of companies like ours that are trading at the level that we're currently trading” — Peter Greenleaf, Executive Chairman · 2026-11-12.

Why the stock disagreed

Olivia Brayer asked the question everyone was thinking — “how are you guys thinking about value creation as an opportunity just relative to the level of dilution that does come with this deal? I think most people were surprised to see this deal, especially just given how early you are into Zelsuvmi's launch still.” — Olivia Brayer, Analyst · 2026-11-12 Management is in the quiet period before the S-4 and repeatedly declined to elaborate on D-Fi's profile. That communication vacuum, over a stock-based acquisition of a pre-revenue asset at a $31.6M market cap, is exactly the setup for a -57% three-week drawdown. It matters because the base business is not yet self-funding. Net income was -$23M in the latest quarter, with free cash flow of roughly -$10M. The company drew $10M more on its Horizon facility on October 30 and can access another $10M only if it hits $70M trailing-twelve-month net revenue. The whole thesis — cash-generating commercial base funding a late-stage rare-disease pivot — hinges on Zelsuvmi accelerating precisely when its sequential growth has stalled.

It brings us into the rare disease space. It gets us out of just a value orientation and puts us into a growth biotech orientation ... for an upfront consideration of equity. And if successful, milestone payments upon data and approval of the drug.

Peter Greenleaf, Executive Chairman · 2026-11-12

What's left of the launch story

Strip out the deal and there is a coherent, if slower, operating narrative: Xepi (impetigo) planned for a March 2027 launch, Xeglyze (head lice) by Q3 2027, both slipped into an existing field force that management says needs no material SG&A step-up. The resistance argument for Xepi against generic mupirocin/Naprosyn is the freshest genuine clinical-commercial idea on the call — though Scott conceded the data is "all over the board right now." Importantly, the prior calls show Xepi timing has been pushed before (March 2027 was already the refrain in August), and the March 2026 call's promise that the company would “cross over the line” — Francis Knuettel, Chief Financial Officer · 2026-03-19 on profitability by year-end now looks swept aside by a deal that resets the story entirely. The tell is in the keyword shift. ZELSUVMI launch and new prescriber — the twin engines of the 2026 narrative — fell to the decliners list this quarter, while biotech, pivot, and Castle Creek surged into the gainers. Management didn't just add a pipeline; it changed what kind of company it is asking investors to underwrite, in the same quarter its lead product went flat. The S-4 is the next real catalyst. Until then, the market has voted — and it voted against paying for the next drug with the current one's stock.